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Abstract
Background: Insulin glargine (glargine) and insulin NPH (NPH) are two basal insulin treatments.
This study investigated the effect on glycaemic control of switching from a NPH-based regimen to
a glargine-based regimen in 701 patients with type 1 (n= 304) or type 2 (n= 397) diabetes, using
unselected primary care data.
Methods: Data for this retrospective observational study were extracted from a UK primary care
database (The Health Improvement Network). Patients were required to have at least 12 months
of data before and after switching from NPH to glargine. The principal analysis was the change in
HbA1c after 12 months treatment with glargine; secondary analyses included change in weight and
total daily insulin dose. Inconsistent reporting of hypoglycemic episodes precludes reliable
reporting of this outcome. Multivariate analyses were used to adjust for baseline characteristics and
confounding variables.
Results: After adjustment, both diabetic cohorts showed statistically significant reductions in mean
HbA1c 12 months after the switch, by 0.38% (p < 0.001) in type 1 patients and 0.31% (p < 0.001) in
type 2 patients. Improvement in HbA1c was positively correlated with baseline HbA1c; patients with
baseline HbA1c ≥ 8% had reductions of 0.57% (p < 0.001) and 0.47% (p < 0.001), respectively. There
was no significant change in weight or total daily insulin dose while on glargine. The majority of
patients received a basal-bolus regimen prior to and after the switch (mean 79.3% before and 77.2%
after switch in type 1 patients, and 80.4% and 76.8%, respectively in type 2 patients, p > 0.05).
Conclusion: In routine clinical practice, switching from NPH to glargine provides the opportunity
for improving glycaemic control in diabetes patients inadequately controlled by NPH.
Background
Tight glycaemic control is a mandatory component of dia-
betes care given proven beneficial effects on the risk of
vascular complications [1,2]. Current UK, European and
US guidelines [3-9] recommend a target for glycated hae-
moglobin (HbA1c) between 6.5% and 7.5%. Insulin rep-
resents the cornerstone of care for achieving this target in
patients with type 1 diabetes, and is also indicated in type
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2 diabetes patients with suboptimal glycaemic control
despite increasingly aggressive therapy with oral antidia-
betic drugs (OADs) in addition to lifestyle changes.
In clinical practice, concerns about the initiation of insu-
lin therapy contribute to less than optimal glycaemic con-
trol. As well, titration of insulin so as to achieve accepted
targets for HbA1c while minimising the risk of hypoglycae-
mia and weight gain, may be problematic with conven-
tional insulin regimens. The pharmacokinetic profile of
short-acting basal insulins such as Neutral Protamine
Hagedorn (NPH) are less than satisfactory for achieving a
sustained duration of action. In contrast, more prolonged
and predictable absorption is observed after administra-
tion of insulin glargine (glargine, Lantus®), the first long-
acting basal analogue product. Following injection,
glargine precipitates into the subcutaneous tissue and
then dissociates slowly to form monomers that enter the
circulation in a controlled fashion for 24 hours [10]. In
clinical trials in patients with type 1 or type 2 diabetes,
glargine was shown to be as effective as NPH insulin in
lowering HbA1c levels [11,12] and was also associated
with significantly fewer episodes of symptomatic and noc-
turnal hypoglycaemia [13]. In addition, most patients
were adequately controlled by a once daily injection, due
to the more prolonged and stable mechanism of action
[14,15], leading to improved patient satisfaction [16].
Given the need to balance glycaemic control with the risk
of hypoglycaemia, glargine may therefore offer benefits
over NPH [17].
It is recognised that findings from randomised clinical tri-
als are not necessarily representative of everyday clinical
practice, particularly in respect of patient populations and
adherence to medication [18,19]. Several observational
studies [20-24] have attempted to address this issue.
While these studies suggested that the use of glargine
improved glycaemia control compared with NPH, defi-
ciencies in patient selection and control for 'regression to
the mean' effects and potential confounding variables
make these analyses difficult to interpret. Therefore, we
conducted a retrospective observational study based on a
large patient cohort derived from primary care practices in
the UK to assess the impact on HbA1c, weight and insulin
use of switching from NPH to glargine.
Methods
Data source
The data were sourced from a large national computerised
medical record database known as The Health Improve-
ment Network (THIN), which includes data from 211 UK
primary care practices collected over a 15 year period from
about 5 million patients, of whom 2.34 million were
actively registered with a practice and prospectively fol-
lowed [25]. The THIN database is not supported by any
industrial sponsor, nor biased towards any particular dis-
ease group. THIN data on patient demographics, medical
history, test results and drug treatments are collected in a
non-interventional manner during daily record keeping
within the primary care practice. To ensure confidentiality
of patient information, the data are anonymised at the
collection stage using encrypted identifiers for the physi-
cian and individual. Ethical approval for this study was
obtained from the London Multiple Research Ethics Com-
mittee (Number 06/MRE02/32) before commencing data
extraction.
From data collected between July 2002 and December
2005, as described previously [26,27], 137,258 patients
were identified as diabetic based on a relevant medical
diagnosis via the Read code system [28], or prescription of
OAD. Diagnosis of diabetes was attributed in a stepwise
manner. For patients without a specific diagnosis of dia-
betes, a diagnosis of type 2 diabetes was attributed if the
subject had received any non-insulin, diabetes-related
medication. Overall, 90% of patients were identified with
type 2 diabetes.
Individuals were included in the current analysis if they
had 1) been prescribed NPH for at least 12 months prior
to switching to a glargine-based regimen, and 2) contin-
ued treatment with glargine for at least 12 months. Treat-
ment with OADs and/or bolus of prandial insulin was
permitted in addition to basal glargine. For this study we
also extracted information on associated comorbidities
including: myocardial infarction, stroke, peripheral vascu-
lar disease, peripheral neuropathy, nephropathy and
retinopathy. Use of analogue and human prandial insu-
lins could not be distinguished from information col-
lected.
Study design and outcome measures
This was a retrospective, 24-month non-randomised,
observational study. The principal analysis was glycaemic
control as assessed by HbA1c. Measurements were per-
formed locally in each centre and mean HbA1c values were
calculated every 3 months before and after switching insu-
lin therapy using actual or linearly interpolated values.
Although much of the UK is currently HbA1c  DCCT-
aligned, and primary care practices use National Health
Service hospital laboratories which are members of qual-
ity assurance schemes, the degree of standardisation at the
time of data collection (2002–2006) is not known. How-
ever, our study depends on change in HbA1c and will thus
be less sensitive to differences in calibration between
assays. Secondary analyses included mean change in
weight (kg) calculated as for HbA1c, mean change in pre-
scribed daily insulin dose calculated as units prescribed
divided by the number of days covered by the prescrip-
tion, the proportion of patients using bolus prandial insu-Cardiovascular Diabetology 2009, 8:3 http://www.cardiab.com/content/8/1/3
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lin, and the percentage of patients achieving defined
HbA1c  levels. Self-reported episodes of hypoglycaemia
were recorded by general practitioners during each 3
monthly interval.
Statistical methods
Linear interpolation of missing data was performed where
a patient had at least 2 data measurement during each 12
month period (prior to and following switch) and data
was not missing during two consecutive 3 monthly inter-
vals. Unadjusted results for the principle (HbA1c) and sec-
ondary analyses used linearly interpolated data and were
summarised using descriptive statistics. For the unad-
justed results the mean change during the 12 month prior
to and following the switch was calculated. Comparisons
were performed using paired t-tests. Graphical analyses
were based on linearly interpolated data, which provides
a clearer graphical interpretation of the results.
For the principle analysis of change in HbA1c a multivari-
ate analysis using actual patient data was performed.
Actual patient data was preferred over interpolated values;
multivariate models constructed using the later showing
no appreciable effect on the model specification or statis-
tical inference. Data was assessed in a linear mixed effect
modelling framework, adjusting for repeated measures
per patient over time, with change in HbA1c relative to
time of insulin initiation as the dependent variable with
the following pre-defined (fixed-effects) exploratory cov-
ariates; age, weight, sex, type of diabetes, number of OADs
used prior to commencing insulin, number of OADs used
in combination with insulin at initiation, disease dura-
tion, presence of hypoglycaemia and associated co-mor-
bidities during the study.
Multivariate models were developed with SPSS for Win-
dows (version 8; SPSS, Chicago, IL, USA) using a back-
ward stepwise approach; non-significant variables at the
5% level were excluded. Sensitivity analyses were per-
formed to consider treatment effect by baseline HbA1c lev-
els. Secondary endpoints were summarised descriptively.
Results
Subjects and baseline characteristics
A total of 701 patients, 304 (43%) with type 1 diabetes
and 397 (57%) with type 2 diabetes, were included in the
study. Mean HbA1c at baseline before switching was simi-
lar in each group (8.8% and 8.9%, respectively) (Table 1).
In total, 22% of patients with type 2 diabetes received an
OAD prior to the switch. The majority of patients received
a basal-bolus NPH-based regimen prior to the switch
(Table 1).
Change in HbA1c
Mean HbA1c was stable and similar in both type 1 and
type 2 diabetic cohorts in the 12 months prior to the
switch to glargine (Figure 1A). After 12 months on
glargine, unadjusted mean HbA1c levels decreased signifi-
Table 1: Baseline characteristics of patients switching from NPH to glargine
Type 1 Type 2
n (%) 304 (43.4) 397 (56.6)
% male 47.4 52.4
Age (years)* 34.8 ± 13.2 48.2 ± 13.8
Weight (kg) 76.6 ± 14.7 82.9 ± 16.7
Baseline HbA1c*† 8.8 ± 1.5 8.9 ± 1.4
Duration of diabetes (years) ‡ 13.4 ± 10.0 10.0 ± 8.6
Number of co-morbidities*§ 1.7 ± 1.3 1.9 ± 1.3
Proportion of patients receiving OAD(s) (%) 2 22
OAD per patient before starting insulin*¶ 0.0 ± 0.0 0.2 ± 0.4
Proportion of patients receiving bolus doses (%)
At any point in prior 12 months 97 91
In prior 3 months 79 80
Hypoglycaemia episodes in a 3 month period*||
No. episodes 36 40
Mean no. episodes per patient 0.12 0.10
OAD = oral antidiabetic drugs; HbA1c = glycated haemoglobin. Data are mean ± SD unless indicated.
*Significant variables investigated in multivariate analysis.
†Data missing for 30 patients with type 1 diabetes and 39 patients with type 2 diabetes.
‡Data missing for 3 patients with type 1 diabetes and 8 patients with type 2 diabetes.
§Includes myocardial infarction, stroke, peripheral vascular disease, neuropathy, nephropathy, and retinopathy. Data available for 57 patients with 
type 1 diabetes and 76 patients with type 2 diabetes.
¶Number of oral diabetic treatments (e.g. metformin, sulfonylureas) prescribed prior to commencing insulin. Data missing for 100 patients with 
type 2 diabetes.
||Number of hypoglycaemic episodes reported during the 3 month period prior to switch. Hypoglycaemic episodes were reported in 30 patients 
with type 1 diabetes and 33 patients with type 2 diabetes.Cardiovascular Diabetology 2009, 8:3 http://www.cardiab.com/content/8/1/3
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Mean HbA1C 12 months before and after switching from NPH to glargine (A), mean change in HbA1c after switch (B), use of  bolus insulin before and after switch (C) and total daily insulin dose before and after switch (D) (unadjusted data) Figure 1
Mean HbA1c 12 months before and after switching from NPH to glargine (A), mean change in HbA1c after 
switch (B), use of bolus insulin before and after switch (C) and total daily insulin dose before and after switch 
(D) (unadjusted data). The last measurement for NPH is at -3 months (indicated by vertical dotted line). During period -12 
m to -3 m patients are taking NPH only. During 3 month switch time point (0 months) patients may be prescribed NPH or 
glargine. During period +3 m to +12 m patients are only prescribed glargine. Linearly interpolated data were used to graphi-
cally depict the change in each parameter. Linearly interpolated data affords a clearer graphical interpretation but may bias esti-
mates of variance; as such error bars (95% confidence intervals for the means) are not reported. Total daily insulin dose was 
calculated according to the number of units prescribed divided by the number of days covered by the prescription.
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Table 2: Adjusted HbA1c reduction over 12 months in patients switching from NPH to glargine*
Type 1 (n = 304) Type 2 (n = 397)
Variable No. Δ HbA1c (%) p-value† No. Δ HbA1c (%) p-value†
Overall 304 -0.38 <0.001 397 -0.31 <0.001
HbA1c by baseline level
≥ 7% 259 -0.42 <0.001 327 -0.36 <0.001
≥ 8% 186 -0.57 <0.001 271 -0.47 <0.001
≥ 9% 107 -0.96 <0.001 162 -0.69 <0.001
≥ 10% 53 -1.07 <0.001 71 -0.97 <0.001
*Adjusted for significantly correlated demographic and clinical covariates including concomitant use of bolus, age, weight, hypoglycaemia, and 
baseline HbA1c (in the 3 months prior to insulin initiation).
†p-values by the paired t-test for difference in mean HbA1c following switch from NPH to glargine.Cardiovascular Diabetology 2009, 8:3 http://www.cardiab.com/content/8/1/3
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cantly by 0.32% in both cohorts (from 8.81% at baseline
to 8.49%, p = 0.003 in the type 1 cohort and from 8.93%
to 8.61%, p = 0.0004 in the type 2 cohort) (Figures 1B and
1C). After adjustment for significant demographic and
clinical covariates, including age, weight, baseline HbA1c,
concomitant bolus usage and hypoglycaemia, the
decrease in mean HbA1c over 12 months was 0.38% (p <
0.001) in type 1 diabetes patients and 0.31% (p < 0.001)
in type 2 diabetes patients. Sensitivity analyses showed
that improvement in HbA1c after switching was positively
correlated with baseline HbA1c. Patients with baseline
HbA1c ≥ 10% had the greatest reduction in mean HbA1c (-
1.07%, p < 0.001 in the type 1 diabetes cohort and -
0.97%, p < 0.001 in the type 2 diabetes cohort) (Table 2).
Age did not significantly influence the change in HbA1c
following the switch (data not shown).
Proportion of patients reaching HbA1c levels
In both cohorts, 31% of patients achieved an HbA1c level
of 7% within 12 months of switching from NPH to
glargine. Overall, 18% of patients with type 1 diabetes and
20% with type 2 diabetes achieved a reduction in HbA1c
of ≥ 1%.
Episodes of hypoglycaemia
During the 12 months prior to the switch from NPH to
glargine, 115 hypoglycaemic episodes were reported by
the patients with type 1 diabetes (0.38 episodes per
patient/year), while 131 episodes were reported by
patients with type 2 diabetes (0.33 episodes per patient/
year). After switching to glargine, the respective data were
244 episodes for the patients with type 1 diabetes (0.80
episodes per patient/year) and 286 episodes for the
patients with type 2 diabetes (0.72 episodes per patient/
year) during the following 12 months.
Change in use of bolus, total insulin usage and weight
There were no significant changes over the 12 months fol-
lowing the switch with respect to the use of prandial insu-
lin boluses (mean 79.3 ± 4.3% before and 77.2 ± 4.9%
after switching in type 1 patients, and 80.4 ± 4.0% and
76.8 ± 4.3%, respectively in type 2 patients, p > 0.05, Fig-
ure 1C) or the total daily (glargine + prandial) insulin
dose (1.0 ± 2.0 U/kg before and 0.89 ± 1.48 U/kg after
switching in type 1 patients, and 0.96 ± 1.82 U/kg and
0.97 ± 1.44 U/kg in type 2 patients, p > 0.05, Figure 1D).
While there was an initial increase in the calculated total
daily dose of glargine (about 20 U per day) in the first 6
months after the switch in each cohort, this subsequently
stabilised over the next 6 months. This small initial
increase may be due a "stock building effect", whereby
patients are initially prescribed additional insulin doses to
allow them to store a "security stock" when starting the
treatment with their new insulin (daily dose of insulin
was calculated from the quantity of insulin prescribed at
each visit). The use of OADs remained unchanged after
the switch, with quarterly estimates indicating that
between 20% and 22% of patients received OADs. Switch-
ing from NPH to glargine was not associated with any sig-
nificant change in weight (mean weight 76.7 ± 1.8 kg
before and 77.8 ± 2.2 kg 12 months after switching in type
1 patients, and 82.9 ± 1.7 kg and 82.7 ± 2.0 kg, respec-
tively in type 2 patients, p > 0.05).
Discussion
The results of this retrospective observational study show
that patients with type 1 or type 2 diabetes, who switch
from a predominantly basal-bolus NPH-based regimen to
a glargine-based basal-bolus regimen derive significant
improvement in glycaemic control (adjusted mean
decrease in HbA1c by 0.38% and 0.31%, respectively)
within 12 months, without any significant increase in
weight, use of prandial boluses, total insulin dose or OAD
intensity. These findings add to a weight of evidence sup-
portive of improved glycaemic control when patients
switch from other insulins, either NPH [29,30] or
premixed insulins [31], to glargine. The relevance of our
findings are strengthened by the nature and size of our
sample (701 patients in an everyday clinical practice set-
ting), the quality of baseline data (available for at least 12
months prior to switching from NPH to glargine), the
completeness of follow-up data after switching (at least 3
monthly follow-up over 12 months), and the use of linear
interpolation and multiple regression techniques in our
analysis. Sensitivity analyses showed that the magnitude
of improvement in HbA1c was greatest in patients with the
poorest glycaemic control (mean adjusted decreases of
0.57 and 1.07% in type 1, and 0.47 and 0.97% in type 2
diabetes patients with baseline HbA1c levels ≥ 8% and ≥
10%, respectively) (Table 2), and comparable with that
reported in trials of patients newly commencing insulin
therapy [32]. A reduction of 1% in HbA1c is associated
with a 14% reduction in myocardial infarction, a 14%
reduction in all-cause mortality, a 37% reduction in
microvascular complications, and a 21% reduction in
overall diabetic complications [33]. Thus, the additional
reduction in HbA1c achieved by switching to a glargine-
based regimen can be considered clinically meaningful,
both in the overall population and the subgroups which
had a ≥ 1% greater reduction, given the potential to trans-
late to clinical outcomes benefits in the longer-term.
While we have highlighted the strengths of our study, we
also acknowledge a number of potential limitations. First,
we recognise that retrospective observational studies do
not provide the same robust level of evidence as ran-
domised controlled trials. In our study, the decision to
switch from NPH to glargine treatment was not standard-
ised but instead based on the judgement of the individual
treating clinician. The data were collected from a largeCardiovascular Diabetology 2009, 8:3 http://www.cardiab.com/content/8/1/3
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number of primary practice units which is likely to intro-
duce a considerable level of heterogeneity to the main
findings. As well, the level of data collection did not per-
mit investigation of potential influences on glycaemic
control including differences in racial background [23],
body mass index [29,34], frequency of NPH and glargine
use (once vs. twice daily) [35], concurrent use of OADs
with glargine [36], time of administration of glargine
(morning vs. bedtime) [37,38] and patient compliance
[39,40]. Second, it was not possible to reliably assess data
concerning hypoglycaemic episodes in patients who
switch from a NPH-based regimen to a glargine-based reg-
imen. A lack of consistency in recording these data in the
THIN database meant that there is strong likelihood that
we underestimated the real incidence of hypoglycaemia
and only captured the most severe episodes. The inci-
dence of hypoglycaemia may also reflect the self-reporting
methods used, as patients and physicians were not
requested to provide specific details of each episode. The
limitations of the database also did not allow assessment
of the nature (e.g. nocturnal) or severity of hypoglycaemic
episodes before and after the switch. A higher number of
hypoglycaemic episodes were noted after the switch from
NPH to glargine. However, the overall rate of hypoglycae-
mia was low so the results should interpreted with cau-
tion. Should this trend be real, the significant
improvement in glycaemic control observed with glargine
in both diabetic cohorts may have made patients more
susceptible to episodes of hypoglycaemia.
Despite these shortcomings, observational studies such as
the current report are generally regarded as an ideal
approach to assess the actual health outcomes of patients
in routine care, more so than randomised controlled tri-
als. This is because the level of care patients receive in clin-
ical trials is often of a higher standard and not
representative of that provided in daily clinical practice
[18,19]. As well, clinical trials usually have limited scope
for titration of other glucose-lowering drugs, a relatively
short observational period, and potential for population
bias which may prevent extrapolation of their findings to
everyday practice [41,42]. In the current study, there were
no limitations regarding patient inclusion criteria or clin-
ical criteria for switching insulin treatment, which is likely
to widen the implications of our findings. Furthermore,
while high rates of missing data and patient drop-outs are
common criticisms of observational studies, the current
study provided interpolated data for 90% of patients dur-
ing the months preceding and immediately following the
switch and for 67% 12 months later. Interpolated HbA1c
data was used in 60% of patients. However, the main
analysis performed in our study was based on the adjusted
change in HbA1c which only used actual and complete
data values. It is reassuring to note that our findings are
supported by other analyses from different populations
and geographic locations and using different methods of
data collection [29].
The implications of these results for decision makers are
that improvement in control of glycaemia, as measured by
HbA1c, can be directly related to treatment efficacy and the
costs of subsequent care. Using a discrete event simulation
model, we recently reported that that for UK patients with
sub-optimally controlled type 2 diabetes, taking into
account effects on HbA1c and reduction in hypoglycaemia,
glargine can be considered as a cost-effective treatment
option with a cost per quality-adjusted life year of less
than £10,000 [43]. In addition, preliminary data from a
similar analysis using the THIN database indicates that for
patients with type 1 or type 2 diabetes who switch from
NPH to glargine, treatment with glargine is a cost-effective
strategy according to conventional thresholds [44].
A noteworthy finding from our study is that despite dis-
semination of clinical guidelines for diabetes manage-
ment, glycaemic control is still less than optimal in a large
proportion of patients in primary practice in the UK.
Approximately two-thirds of patients in the study failed to
achieve an HbA1c level ≤ 7%. These data highlight the
need for additional treatment strategies. These may
include higher doses and more aggressive titration (in the
current study, evidence that glargine had no significant
effect on weight is suggestive of suboptimal treatment),
greater use of OAD therapy in patients with type 2 diabe-
tes (only 20% were prescribed OAD therapy at the time of
the switch), as well as the use of educational programmes
[45-48].
Conclusion
This observational study suggests that in diabetes patients
treated with NPH and with evidence of suboptimal effi-
cacy and/or poor tolerability, switching to insulin glargine
offers the opportunity for improved glycaemic control.
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